PSCA-POSITIVE PROSTATE CANCER

Clinical trials for PSCA-POSITIVE PROSTATE CANCER explained in plain language.

Never miss a new study

Get alerted when new PSCA-POSITIVE PROSTATE CANCER trials appear

Sign up with your email to follow new studies for PSCA-POSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Engineered immune cells take aim at Hard-to-Treat prostate cancer

Disease control Recruiting now

This early-stage study tests a new treatment called ETB-DualNK-01 for men with advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses donor immune cells (NK cells) that are engineered to target two cancer markers, PSMA and PSCA. The study aims…

Matched conditions: PSCA-POSITIVE PROSTATE CANCER

Phase: PHASE1 • Sponsor: Beijing Biotech • Aim: Disease control

Last updated Jun 16, 2026 12:51 UTC

PSCA-POSITIVE PROSTATE CANCER

Get alerted when new PSCA-POSITIVE PROSTATE CANCER trials appear

Engineered immune cells take aim at Hard-to-Treat prostate cancer